No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC

In fact, the worst survival outcomes were seen with the most commonly used first-line regimen, FOLFOX chemotherapy plus the VEGF inhibitor bevacizumab.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news